|
Comparison
|
Random effects model
|
Fixed effects model
|
|---|
|
Odds ratio (95 % CrI)
|
Odds ratio (95 % CrI)
|
|---|
|
TAC vs. glucocorticoids
|
0.33 (0.12–0.88)
|
0.33 (0.13–0.82)
|
|
TAC vs. CYC
|
0.37 (0.15–0.87)
|
0.37 (0.16–0.82)
|
|
TAC vs. MMF
|
0.40 (0.18–0.81)
|
0.40 (0.20–0.78)
|
|
TAC vs. AZA
|
0.32 (0.12–0.81)
|
0.32 (0.13–0.77)
|
|
CYC LD vs. TAC
|
4.84 (1.48–17.64)
|
4.50 (1.43–14.50)
|
|
HD glucocorticoids vs. TAC
|
12.83 (1.53–119.90)
|
12.22 (1.58–105.70)
|
|
CYC HD vs. TAC
|
6.60 (2.25–20.50)
|
6.52 (2.38–18.95)
|
|
MMF-AZA vs. CYC LD
|
0.09 (0.01–0.76)
|
0.09 (0.01–0.74)
|
|
MMF-AZA vs. HD glucocorticoids
|
0.03 (0.00–0.56)
|
0.21 (0.02–1.79)
|
|
MMF-AZA vs. CYC HD
|
0.07 (0.01–0.54)
|
0.07 (0.01–0.47)
|
|
MMF-AZA vs. CYC-AZA
|
0.14 (0.02–0.71)
|
0.14 (0.02–0.65)
|
|
Residual deviance
|
72.49
|
74.9
|
|
Number of unconstrained data points
|
71
|
71
|
|
Deviance information criteria
|
325.646
|
325.51
|
- All odds ratios are statistically significant
- Odds ratios from either model are very similar to each other, denoting the robustness of the analyses, regardless of assumptions
- CYC cyclophosphamide, MMF mycophenolate mofetil, AZA azathioprine, TAC tacrolimus, HD high dose, LD low dose; when not specified, standard dose should be inferred
